At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
talazoparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AN OPEN-LABEL, SINGLE-ARM, PHASE 1 STUDY OF PHARMACOKINETICS, SAFETY AND ANTI-TUMOR ACTIVITY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
In Brief
A Phase 1 clinical trial evaluating talazoparib for Neoplasms. Completed, enrolled 15 participants across 2 sites.
Detailed Summary
A phase1 study to evaluate the PK (single dose and multiple doses) and safety of talazoparib 1 mg Once Daily in Chinese adult participants with advanced solid tumors. A maximum of approximately 15 participants will be enrolled such that approximately 12 evaluable participants complete the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartNov 2020
Primary CompletionAug 2021
Study CompletionDec 2021
TodayJul 2026
First PostedNov 19, 2020
Enrollment StartNov 30, 2020
Primary CompletionAug 8, 2021
Study CompletionDec 14, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.6 years ago
Interventions
talazoparibdrug
Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.